Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$4.34 - $5.84 $1.17 Million - $1.58 Million
269,873 Added 24.07%
1,391,302 $8.13 Million
Q3 2022

Nov 14, 2022

BUY
$4.27 - $7.2 $2.26 Million - $3.82 Million
530,305 Added 89.71%
1,121,429 $7.51 Million
Q2 2022

Aug 15, 2022

BUY
$2.8 - $6.36 $1.6 Million - $3.63 Million
570,731 Added 2798.66%
591,124 $2.49 Million
Q1 2022

May 16, 2022

SELL
$2.73 - $3.94 $149,852 - $216,270
-54,891 Reduced 72.91%
20,393 $69,000
Q4 2021

Feb 14, 2022

BUY
$2.69 - $4.22 $173,523 - $272,219
64,507 Added 598.56%
75,284 $237,000
Q2 2021

Aug 16, 2021

SELL
$3.77 - $5.24 $28,701 - $39,892
-7,613 Reduced 41.4%
10,777 $45,000
Q1 2021

May 17, 2021

SELL
$4.86 - $13.07 $261,166 - $702,355
-53,738 Reduced 74.5%
18,390 $92,000
Q1 2020

May 15, 2020

SELL
$5.98 - $13.09 $177,037 - $387,529
-29,605 Reduced 29.1%
72,128 $637,000
Q4 2019

Feb 14, 2020

SELL
$5.71 - $9.22 $244,941 - $395,510
-42,897 Reduced 29.66%
101,733 $939,000
Q3 2019

Nov 14, 2019

BUY
$5.88 - $12.35 $391,119 - $821,484
66,517 Added 85.15%
144,630 $850,000
Q2 2019

Aug 14, 2019

BUY
$9.44 - $13.12 $326,454 - $453,715
34,582 Added 79.44%
78,113 $937,000
Q1 2019

May 15, 2019

BUY
$12.07 - $17.54 $55,497 - $80,648
4,598 Added 11.81%
43,531 $0
Q4 2018

Feb 14, 2019

SELL
$11.25 - $16.17 $422,932 - $607,894
-37,594 Reduced 49.13%
38,933 $488,000
Q3 2018

Nov 13, 2018

SELL
$12.82 - $17.88 $309,372 - $431,480
-24,132 Reduced 23.97%
76,527 $0
Q2 2018

Aug 10, 2018

SELL
$16.83 - $21.66 $1.04 Million - $1.34 Million
-61,927 Reduced 38.09%
100,659 $0
Q1 2018

May 11, 2018

BUY
$19.24 - $28.03 $1.78 Million - $2.6 Million
92,625 Added 132.4%
162,586 $3.72 Million
Q4 2017

Feb 09, 2018

SELL
$13.96 - $29.05 $763,863 - $1.59 Million
-54,718 Reduced 43.89%
69,961 $1.81 Million
Q3 2017

Nov 09, 2017

BUY
$13.91 - $15.31 $1.73 Million - $1.91 Million
124,679
124,679 $1.84 Million

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About CONCERT PHARMACEUTICALS, INC.


  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.